Extreme Oncoplastic Surgery for MultifocalMulticentric and Locally Advanced Breast Cancer

Abstract EN

Introduction.

Breast conserving surgery (BCS) followed by radiation therapy (RT) has become the preferred alternative to mastectomy for patients with early stage breast cancer (BC).

Randomized trials have confirmed equivalent locoregional control and overall survival for BCS and mastectomy.

Extreme Oncoplasty (EO) extends the indications of BCS for patients who would otherwise require mastectomy, ensuring better aesthetic outcomes and oncological safety.

Methods.

BC patients with multifocal/multicentric (MF/MC) tumors, extensive DCIS, or large tumor >50mm underwent EO at our breast unit.

Therapeutic reduction mammaplasty (TRM) with wise pattern preoperative markings and dual pedicle technique involving parenchymal rearrangement was used for oncoplastic reconstructions in majority of the cases followed by RT.

Patient reported outcome measures (PROMs) were assessed using the validated Breast-Q questionnaire.

Results.

Of the 39 patients in the study, 36 had unilateral and 3 had bilateral BC.

Mean age was 47.2 years.

Median tumor size was 75mm.

17 (43.6%) patients received NACT; none achieved a complete clinical response.

28 (71.8%) patients were administered to adjuvant chemotherapy.

33(84.6%) patients received RT to the breast with a median dose of 50Gy in 28 fractions and a boost dose of 10Gy in 5 fractions to the tumor bed.

No major complications or local recurrences were observed.

Excellent Breast-Q scores were observed in patients undergoing EO after 12 months of follow-up.

Conclusion.

EO followed by RT results in acceptable local-regional control, low rate of complications, and high patient satisfaction.

In selected patients, EO could provide a safe alternative for breast conservation surgery instead of mastectomy.